Metal Complexes with Schiff Bases as Antimicrobials and Catalysts

Domenico Iacopetta 1,†, Jessica Ceramella 1,†, Alessia Catalano 2,*, Annaluisa Mariconda 3,*, Federica Giuzio 3, Carmela Saturnino 3,*, Pasquale Longo 4 and Maria Stefania Sinicropi 1,†

1 Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy; domenico.iacopetta@unical.it (D.I.); jessica.ceramella@unical.it (J.C.); s.sinicropi@unical.it (M.S.S.)
2 Department of Pharmacy-Drug Sciences, University of Bari “Aldo Moro”, 70126 Bari, Italy
3 Department of Science, University of Basilicata, 85100 Potenza, Italy; annaluisa.mariconda@unibas.it (A.M.); federica.giuzio@unibas.it (F.G.); carmela.saturnino@unibas.it (C.S.)
4 Department of Chemistry and Biology, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy; plongo@unisa.it
* Correspondence: alessia.catalano@uniba.it; Tel.: +39-080-544-2746
† These authors contributed equally to this work.

Abstract: Complexes of Schiff bases (SBs) with metals are promising compounds exhibiting a broad range of applications, such as catalysts, polymers, dyes, and several biological activities, including antimicrobial, anticancer, antioxidant, antimalarial, analgesic, antiviral, antipyretic, and anti-diabetic actions. Considering the crisis that the whole world is now facing against antimicrobial-resistant bacteria, in the present review, we chose to focus on the activity of SBs as antimicrobials, particularly underlining the most recent studies in this field. Finally, some interesting catalytic applications recently described for metal complexes with SBs have also been discussed.

Keywords: Schiff bases; antibacterials; imines; antimicrobials; metal complexes; antifungals

1. Introduction

The widespread usage of SBs in chemistry, industry, medicine, and pharmacy has notably enhanced the interest in these intriguing compounds [1,2]. The functional feature of SBs is represented by the azomethine group \(-\text{C=N-}\), where the substituents may be alkyl, aryl, or heterocyclic groups. The carbon atom of the imine bond is predisposed to nucleophilic addition, whereas the nitrogen atom holds an extremely reactive free electron pair, able to form stable complexes with metals. The catalytic activity of SBs [3], their corrosion inhibition behavior [4], as well as the action as photosensitizers [5], and fluorescent chemo-sensors tools for the detection of Cu\(^{2+}\) and Fe\(^{3+}\) metal ions [6] have been reported. Moreover, numerous biological activities were described in the literature for these compounds [7–9], such as antitumoral [10–12]; antimicrobial [13]; antimalarial [14]; antioxidant; neuroprotective; anti-diabetic; antidepressant [15]; anti-inflammatory [16]; and acetylcholinesterase (AChE)-, butyrylcholinesterase (BChE)- [17–19], and carbonic anhydrase-inhibiting [20] ones. Moreover, coatings made of SBs have been shown to improve the bioactivity of materials, suggesting the use of these compounds in medicine [21].

In a biological context, the azomethine nitrogen of SBs represents a site for the binding of metal ions with numerous biomolecules, including proteins and amino acids, responsible for its biological activities. The highly stable complexes formed by SBs with transition metals often lead to compounds with strongly enhanced activities in inorganic [22,23] and bioinorganic chemistry [24], materials science [25], and pharmacology for biomedical applications [26–30]. The most described biological activities regarding the SBs complexes are antitumoral [31–35], antioxidant [36,37], antidiabetic [38–41], antimalarial [42], antiarthritic [43], antimicrobial [44–48], neuroprotective, catalase-like and catecholase-like...
enzymatic [49,50], and DNA-binding [51,52]. Recently, Aggarwal et al. (2022) [53] underlined the potential applicability of some SBs and their metal complexes for the treatment of COVID-19 [54], which may represent valid alternatives to the classic treatments for this disease [55,56]. Moreover, the liposomal formulation of an SBs complex with arsenic has been described as an agent for drug delivery for the treatment of acute promyelocytic leukemia [57]. The importance of hybrid materials of SB complexes with metals and laccase, an oxygen-reducing enzyme, has also been studied [58]. Recently, stilbene-derivatized SB ligands and their Cu(II) complexes have been suggested as radio-imaging agents for the diagnosis of Alzheimer’s by positron emission tomography when prepared with the positron-emitting radioisotope Cu-64 [59]. Among metals, the coordination chemistry of SBs with inner transition metals, such as lanthanide(III) ions, has promptly progressed in the last decade because of its vast range of applications, specifically in physical applications such as magnetic, luminescence, lasers, optical glasses, telecommunications, biosciences, and numerous biological activities [60,61]. Given the numerous properties of complexes of SBs with metals, we decided to focus on a single activity exerted by this class of compounds. Antimicrobial resistance (AMR) has been declared by the World Health Organization (WHO) to be one of the major global health problems, specifically one of the top ten public health threats worldwide [62,63]. Several studies address the most clinically important pathogens, called ESKAPE pathogens, represented by both Gram-positive and Gram-negative bacteria, namely, Enterococcus faecium and Staphylococcus aureus (Gram-positive bacteria) and Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. (Gram-negative bacteria) [64]. In this context, the purpose of this review was to highlight the antimicrobial activity exerted by SBs complexed with metals dwelling specifically on the most recent studies in this field. Moreover, some interesting studies regarding the catalytic activity of these compounds have been described.

2. SBs Complexes with Metals as Antimicrobials

The antimicrobial activity of some SBs complexes with transition metals is described in this paragraph. Generally, the data refer to the lowest concentration of the tested antimicrobial agent (minimal inhibitory concentration, MIC) that is able to inhibit the visible growth of the bacterium being investigated. Microbes were generally referred to as the American Type Culture Collection (ATCC), the National Collection of Industrial Microorganisms (NCIM), and the Microbial Type Culture Collection (MTCC). Some authors determined the antimicrobial activity by measuring the diameter (as mm) of the zone showing the complete inhibition (inhibition zone diameter, IZD) determined by using the agar well diffusion method. In one article by Kargar et al. (2022) [65], Percentage Mean Mycelial Inhibition (PMMI) is reported against Aspergillus brasiiliensis.

2.1. SBs Complexes with Transition Metals

The antimicrobial activities of some SBs complexes with transition metals recently described are reported in Table 1.

Aroua et al. (2023) [66] described the synthesis and characterization of diverse complexes derived from SBs and the evaluation of their antitumoral, antimicrobial, and insecticide activities. The antibacterial activity was studied against Gram-negative Escherichia coli and Gram-positive Bacillus subtilis (standard drug: tetracycline, IZD = 35 mm and 38 mm, respectively), whereas the antifungal activity was studied against Aspergillus niger (standard drug: nystatin, IZD = 32 mm). Complexes Cl2Cr (1) and CIMn (2) with Cr(III) and Mn(II), respectively, were the most active of the study as antimicrobials.

Alorini et al. (2023) [67] described the synthesis and antitumoral and antimicrobial activities of 2-((E)-(4-((E)-4-chlorobenzylidene)amino)phenyl)iminomethyl)naphthalen-1-ol as SB ligand complexed with Mn(II), Co(III), Ni(II), Cu(II), and Zn(II). The antibacterial and antifungal activities were studied against Salmonella enterica serovar Typhi and Candida albicans, respectively, using gentamycin (IZD = 17 mm against S. enterica ser. Typhi at 10 mg/mL) and clotrimazole (IZD = 21 mm against C. albicans at 10 mg/mL) as standards.
Complex Co(L)(Cl)₂(H₂O)₂ (3) with Co(III) was the most active against the microbial strains used.

Al-Janabi et al. (2023) [68] recently reported an interesting study on metal complexes (Ni(II), Pd(II), Pt(II), Zn(II), and Hg(II)) SBs derived from 4-chloro-3-methyl phenyl hydrazine as dual inhibitors of SARS-CoV-2 and antibacterials. The antibacterial activity was evaluated against S. aureus and P. aeruginosa, and compound 4 showed an interesting activity in comparison to the reference amoxillin (IZD = 29 ± 1.0 mm and 31 ± 0.61 mm against S. aureus and P. aeruginosa, respectively). Interestingly, the compound was also an inhibitor of the main protease (Mpro) of the virus SARS-CoV-2 [69].

Devi et al. (2022) [70] reported the synthesis of sixteen complexes of four SB ligands with transition metals, namely Co(II), Ni(II), Cu(II), and Zn(II), deriving from 4-(benzyloxy)-2-hydroxybenzaldehyde and their in vitro antioxidant, antimicrobial activity, and molecular docking studies. In vitro antimicrobial activities were studied against four bacterial strains (S. aureus, B. subtilis, P. aeruginosa, and E. coli) and two fungal strains (A. niger and C. albicans). Ciprofloxacin (MIC = 0.0047 µmol/mL) and fluconazole (MIC = 0.0051 µmol/mL) against C. albicans and MIC = 0.0102 µmol/mL against A. niger were used as references. Complexes with Ni and Cu (5–8) were the most active against bacteria and fungi. They showed comparable activity to standard drugs against C. albicans. The potential mechanism of action was suggested through molecular modeling studies. Docking of complex 6 with enzyme C. albicans sterol 14-alpha demethylase suggested a hydrophobic binding.

Al-Shboul et al. (2022) [71] described the synthesis, characterization, computational, and biological activity of four SBs derived from 2,2′-diamino-6,6′-dibromo-4,4′-dimethyl-1,1′-biphenyl or 2,2′-diamino-4,4′-dimethyl-1,1′-biphenyl, and 3,5-dichloro- or 5-nitrosalicylaldehyde, and their complexes with Fe(II), Cu(II), and Zn(II), obtained by reaction with copper-, iron-, and zinc-acetate. The compounds were tested for their antibacterial activity against Gram-positive (Micrococcus luteus, S. aureus) and Gram-negative (E. coli) bacteria, using amoxicillin as a reference drug (IZD: 25, 35, and 10 mm, respectively). The complexes with Zn (Z3Zn, 10) and Fe (Z4Fe, 11) showed slight activity against S. aureus, even though lower than the reference. The complex with Zn (Z3Zn, 10) showed the same antibacterial activity as standard drugs against C. albicans. The only complexes with copper (Z1Cu, 12 and Z3Cu, 13) were active against Gram-negative E. coli, with Z3Cu (13) exerting higher activity than the reference.

Abdel-Rahman et al. (2022) [72] described five complexes with Co(II), Ni(II), VO(II), Cr(III), and La(III) synthesized from a tridentate NNO monobasic chelating SB ligand (Z)-2-((pyridin-2-ylmino)methyl)phenol. The complexes were tested for their antimicrobial, antioxidant, and antitumoral activities. Antimicrobial activities were studied against S. aureus, K. pneumoniae, E. coli, and Streptococcus mutans, a pathogen of dental caries [73]. All the complexes showed slight to high antimicrobial activity, with the exception of the complex with V and La against K. pneumoniae. The most interesting activity was observed for the NiL complex (14), which showed antibacterial activity similar to or higher than the references gentamicin and ampicillin. Gentamicin was used as a standard for Gram-negative bacteria (E. coli, IZD = 27 ± 0.5 mm; and K. pneumoniae, IZD = 25 ± 0.5 mm) and ampicillin for Gram-positive bacteria (S. aureus IZD = 22 ± 0.1 mm and S. mutans, IZD = 30 ± 0.5 mm). The IZD value of NiL complex (14) against E. coli was even higher than the reference gentamicin. Both complexes NiL (14) and LaL (15) showed slight activity with respect to ampicillin against S. aureus.

Daravath et al. (2022) [74] reported a study on three SBs complexes with copper (16–18) and their antimicrobial activities against bacteria and fungi not generally investigated, namely Gram-positive Bacillus amyloliquefaciens and Sclerotium rolfsii and Macrophomina phaseolina fungal strains. The study was also carried on against Gram-negative E. coli. Streptomycin was used as the reference against bacteria (IZD = 25 ± 0.17 mm and 25 ± 0.15 mm against B. amyloliquefaciens and E. coli, respectively), whereas mancozeb was used as the reference against fungi (IZD = 24 ± 0.14 mm and 25 ± 0.15 mm, respectively).
Kargar et al. (2022) [65] described the synthesis of two complexes formed between mono and dinuclear SBs and Zn(II) (Z1, 19 and Z2, 20, respectively) and their biological activities as antimicrobial agents against two Gram-positive (S. aureus and B. cereus) and two Gram-negative (E. coli and P. aeruginosa) bacterial strains. The two compounds showed slight activity against Gram-positive bacteria compared with standard chloramphenicol (IZD = 30 mm) and Gram-negative E. coli (chloramphenicol, IZD = 33 mm), whereas they demonstrated interesting activity against the Gram-negative bacterium P. aeruginosa, being more active than the reference (chloramphenicol, IZD = 11 mm). The complexes showed significant antifungal activity against C. albicans ( clotrimazole, IZD = 25 mm), while they were inactive against A. brasiliensis.

Hajari et al. (2022) [75] described the synthesis and biological activity of several 15-membered ring symmetrical pentaaza macrocyclic SBs complexed with Zn(II), Mn(II), and Cd(II), namely [ZnLBr]ClO$_4$, [MnLBr]ClO$_4$ and [CdLBr]ClO$_4$ (21–23) and their cytotoxicity, antibacterial, and antioxidant activities. The antibacterial activity was studied against Gram-positive (S. aureus, B. subtilis, and Listeria monocytogenes) and Gram-negative (E. coli, Klebsiella oxytoca, and Salmonella typhimurium), and the complexes showed moderate effectiveness against all the tested bacteria. The references used were penicillin, ampicillin, vancomycin, and tetracycline. The most active were vancomycin (IZD = 14, 18, 24 mm against S. aureus, B. subtilis, and L. monocytogenes, respectively, and IZD = 22, 20, and 18 mm against E. coli, K. oxytoca, and S. typhimurium, respectively) and tetracycline (IZD = 27, 23, 27 mm against S. aureus, B. subtilis, and L. monocytogenes, respectively, and IZD = 29, 29, and 24 mm against E. coli, K. oxytoca, and S. typhimurium, respectively). S. aureus was the most resistant bacterium, whereas, interestingly, high activity was found for all three complexes against Gram-negative E. coli.

Jyothi et al. (2022) [76] described the study of Co(II) complexes with N-methyl thiosemicarbazide SBs for their cytotoxicity, DNA binding, and antimicrobial studies. The most interesting results were found for complex II (24) against Gram-positive B. subtilis and fungus Fusarium Oxysporium Lycopersicum, even though with lower activity than references in both cases (penicillin, IZD between 15 and 16 mm against B. subtilis and ketoconazole, IZD between 15 and 16 mm against F.O. Lycopersicum).

Li et al. (2022) [77] described the design, synthesis, and biological evaluation of dinuclear Bi(III) complexes with isoniazid-derived SBs. The antibacterial activity was tested against Gram-positive S. aureus and B. subtilis (references vancomycin: MIC = 2 and 0.5 µg/mL; kanamycin, MIC = 2.5 and 1.125 µg/mL; tetracycline, MIC = 0.125 and 0.125 µg/mL against S. aureus and B. subtilis, respectively) and Gram-negative E. coli and P. aeruginosa (references kanamycin, MIC = 8 and >128 µg/mL; tetracycline, MIC = 4 and 32 µg/mL against E. coli and P. aeruginosa, respectively). Complexes 4a and 5a (25 and 26) were the most interesting of the series.

Saroya et al. (2022) [78] described a study on organotin(IV) complexes derived from tridentate SBs and their antimicrobial and antioxidant activities. The antibacterial activity was studied against Gram-positive B. subtilis (MTCC 441) and S. aureus (MTCC 2901) and two Gram-negative E. coli (MTCC 732) and P. aeruginosa (MTCC 424) (ciprofloxacin, MIC = 0.00471 µmol/mL against all bacteria). The antifungal potency was examined against two fungal strains: C. albicans (MTCC 227) and A. niger (MTCC 9933) (fluconazole, MIC = 0.01020 µmol/mL against both fungi strains). Compound 27 was the most active, casually showing the same MIC value of 0.01080 µmol/mL against bacteria and fungi.
Table 1. SBs metal complexes with transition metals with antibacterial activities.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="Structure 1" /></td>
<td>C_{18}H_{16}O_{2}N_{3} Cl_{2}Cr (1)</td>
<td>IZD = 23 mm (E. coli) IZD = 24 mm (S. subtilis) IZD = 22 mm (A. niger)</td>
<td>Aroua et al. (2023) [66]</td>
</tr>
<tr>
<td><img src="image2" alt="Structure 2" /></td>
<td>C_{18}H_{16}O_{2}N_{3} ClMn (2)</td>
<td>IZD = 26 mm (E. coli) IZD = 24 mm (S. subtilis) IZD = 25 mm (A. niger)</td>
<td>Aroua et al. (2023) [66]</td>
</tr>
<tr>
<td><img src="image3" alt="Structure 3" /></td>
<td>(Co(L)(Cl)(H_{2}O)_{2} (3)</td>
<td>IZD = 15 mm (S. enterica ser. typhi at 30 mg/mL) IZD = 19 mm (C. albicans at 30 mg/mL)</td>
<td>Alorini et al. (2023) [67]</td>
</tr>
<tr>
<td><img src="image4" alt="Structure 4" /></td>
<td></td>
<td>MIC = 25 ± 1.10 mm (S. aureus) MIC = 28 ± 1.10 mm (P. aeruginosa)</td>
<td>Al-Janabi et al. (2023) [68]</td>
</tr>
<tr>
<td><img src="image5" alt="Structure 5" /></td>
<td>5</td>
<td>MIC = 0.0225 µmol/mL (S. aureus MTCC 2901) MIC = 0.0112 µmol/mL (B. subtilis NCIM 2063) MIC = 0.0225 µmol/mL (E. coli MTCC 732) MIC = 0.0112 µmol/mL (P. aeruginosa MTCC 424) MIC = 0.0056 µmol/mL (C. albicans MTCC 227) MIC = 0.0112 µmol/mL (A. niger MTCC 9933)</td>
<td>Devi et al. (2022) [70]</td>
</tr>
<tr>
<td><img src="image6" alt="Structure 6" /></td>
<td>6</td>
<td>MIC = 0.0223 µmol/mL (S. aureus MTCC 2901) MIC = 0.0223 µmol/mL (B. subtilis NCIM 2063) MIC = 0.0223 µmol/mL (E. coli MTCC 732) MIC = 0.0111 µmol/mL (P. aeruginosa MTCC 424) MIC = 0.0055 µmol/mL (C. albicans MTCC 227) MIC = 0.0111 µmol/mL (A. niger MTCC 9933)</td>
<td>Devi et al. (2022) [70]</td>
</tr>
</tbody>
</table>
Table 1. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Structure 7" /></td>
<td>7</td>
<td>MIC = 0.0114 μmol/mL (S. aureus MTCC 2901)</td>
<td>Devi et al. (2022) [70]</td>
</tr>
<tr>
<td><img src="image2.png" alt="Structure 8" /></td>
<td>8</td>
<td>MIC = 0.0113 μmol/mL (S. aureus MTCC 2901)</td>
<td>Devi et al. (2022) [70]</td>
</tr>
<tr>
<td><img src="image3.png" alt="Structure Z2Zn" /></td>
<td>Z2Zn  (9)</td>
<td>IZD = 15 mm (M. luteus ATCC 934)</td>
<td>Al-Shboul et al. (2022) [71]</td>
</tr>
<tr>
<td><img src="image4.png" alt="Structure Z3Zn" /></td>
<td>Z3Zn  (10)</td>
<td>IZD = 25 mm (M. luteus ATCC 934)</td>
<td>Al-Shboul et al. (2022) [71]</td>
</tr>
<tr>
<td><img src="image5.png" alt="Structure Z4Fe" /></td>
<td>Z4Fe  (11)</td>
<td>IZD = 20 mm (S. aureus ATCC 29213)</td>
<td>Al-Shboul et al. (2022) [71]</td>
</tr>
<tr>
<td>Structure</td>
<td>Compd</td>
<td>MIC or IZD</td>
<td>Ref.</td>
</tr>
<tr>
<td>-----------</td>
<td>-------</td>
<td>----------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td><img src="image1.png" alt="Image" /></td>
<td>Z1Cu (12)</td>
<td>IZD = 10 mm (E. coli ATCC 25922)</td>
<td>Al-Shboul et al. (2022) [71]</td>
</tr>
<tr>
<td><img src="image2.png" alt="Image" /></td>
<td>Z3Cu (13)</td>
<td>IZD = 20 mm (E. coli ATCC 25922)</td>
<td>Al-Shboul et al. (2022) [71]</td>
</tr>
</tbody>
</table>
| ![Image](image3.png) | NiL (14) | IZD = 31.6 ± 0.6 mm (E. coli ATCC 10536)  
IZD = 20.3 ± 0.6 mm (K. pneumoniae ATCC 10031)  
IZD = 21.3 ± 0.6 mm (S. aureus ATCC 13565)  
IZD = 17.9 ± 0.5 mm (S. mutans ATCC 25175) | Abdel-Rahman et al. (2022) [72] |
| ![Image](image4.png) | LaL (15) | IZD = 20 ± 0.21 mm (B. amyloliquefaciens)  
IZD = 19 ± 0.16 mm (E. coli)  
IZD = 18 ± 0.18 mm (S. rolfsii)  
IZD = 18 ± 0.15 mm (M. phaseolina) | Daravath et al. (2022) [74] |
Table 1. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Image" /></td>
<td>17</td>
<td>IZD = 17 ± 0.14 mm (B. amyloliquefaciens) IZD = 16 ± 0.21 mm (E. coli) IZD = 15 ± 0.24 mm (S. rolfsii) IZD = 16 ± 0.16 mm (M. phaseolina)</td>
<td>Daravath et al. (2022) [74]</td>
</tr>
<tr>
<td><img src="image2.png" alt="Image" /></td>
<td>18</td>
<td>IZD = 16 ± 0.18 mm (B. amyloliquefaciens) IZD = 16 ± 0.15 mm (E. coli) IZD = 14 ± 0.15 mm (S. rolfsii) IZD = 15 ± 0.19 mm (M. phaseolina)</td>
<td>Daravath et al. (2022) [74]</td>
</tr>
<tr>
<td><img src="image3.png" alt="Image" /></td>
<td>Z1 (19)</td>
<td>IZD = 16 mm (S. aureus ATCC 25923) IZD = 15 mm (B. cereus ATCC 11778) IZD = 11 mm (E. coli ATCC 25922) IZD = 12 mm (P. aeruginosa ATCC 15442) PMMI = 22.8 mm (A. brasiliensis ATCC 16404) IZD = 22 mm (C. albicans ATCC 10231)</td>
<td>Kargar et al. (2022) [65]</td>
</tr>
<tr>
<td><img src="image4.png" alt="Image" /></td>
<td>Z2 (20)</td>
<td>IZD = 18 mm (S. aureus ATCC 25923) IZD = 14 mm (B. cereus ATCC 11778) IZD = 13 mm (E. coli ATCC 25922) IZD = 12 mm (P. aeruginosa ATCC 15442) PMMI = 22.8 mm (A. brasiliensis ATCC 16404) IZD = 23 mm (C. albicans ATCC 10231)</td>
<td>Kargar et al. (2022) [65]</td>
</tr>
</tbody>
</table>
Table 1. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="Structure of ZnLBrClO₄" /></td>
<td>[ZnLBr]ClO₄ (21)</td>
<td>IZD = 14 mm (S. aureus) IZD = 15 mm (B. subtilis) IZD = 19 mm (L. monocytogenes) IZD = 28 mm (K. oxytoca) IZD = 21 (S. thypimurium)</td>
<td>Hajari et al. (2022) [75]</td>
</tr>
<tr>
<td><img src="image" alt="Structure of MnLBrClO₄" /></td>
<td>[MnLBr]ClO₄ (22)</td>
<td>IZD = 12 mm (S. aureus) IZD = 17 mm (L. monocytogenes) IZD = 22 mm (K. oxytoca) IZD = 19 (S. thypimurium)</td>
<td>Hajari et al. (2022) [75]</td>
</tr>
<tr>
<td><img src="image" alt="Structure of CdLBrClO₄" /></td>
<td>[CdLBr]ClO₄ (23)</td>
<td>IZD = 17 mm (S. aureus) IZD = 16 mm (L. monocytogenes) IZD = 24 mm (E. coli) IZD = 18 mm (K. oxytoca) IZD = 21 (S. thypimurium)</td>
<td>Hajari et al. (2022) [75]</td>
</tr>
<tr>
<td><img src="image" alt="Structure of II" /></td>
<td>II (24)</td>
<td>IZD between 11 and 12 mm (B. subtilis) IZD between 11 and 12 mm (F.O. Lycopersicum)</td>
<td>Jyothi et al. (2022) [76]</td>
</tr>
<tr>
<td><img src="image" alt="Structure of 4a" /></td>
<td>4a (25)</td>
<td>MIC = 4 µg/mL (S. aureus) MIC = 8 µg/mL (B. subtilis) MIC = 8 µg/mL (E. coli) MIC = 8 µg/mL (P. aeruginosa)</td>
<td>Li et al. (2022) [77]</td>
</tr>
</tbody>
</table>
Table 1. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
</table>
| ![Structure](image1.png) | 5a (26) | MIC = 4 µg/mL (S. aureus)  
MIC = 4 µg/mL (B. subtilis)  
MIC = 8 µg/mL (E. coli)  
(P. aeruginosa) | Li et al. (2022) [77] |
| ![Structure](image2.png) | 27 | MIC = 0.01080 µmol/mL (B. subtilis MTCC 441)  
MIC = 0.01080 µmol/mL (E. coli MTCC 732)  
MIC = 0.01080 µmol/mL (P. aeruginosa MTCC 424)  
MIC = 0.01080 µmol/mL (C. albicans MTCC 227)  
MIC = 0.01080 µmol/mL (A. niger MTCC 9933) | Saroya et al. (2022) [78] |

2.2. SBs Complexes with Inner Transition Metals (Lanthanides and Actinides) as Antimicrobials

Complexes with inner transition metals, such as lanthanides and actinides, have often shown interesting results. Complex LaL (15) by Abdel-Rahman et al. (2022) [72] has been described in the previous paragraph. Other antimicrobial activities of lanthanide complexes with SBs are summarized below (Table 2).

Andiappan et al. (2023) [79] reported the study of several metal complexes of SBs with rare earth (Er, Pr, and Yb) inorganic metals, Schiff-Er (28), Schiff-Yb (29), and Schiff-Pr (30), as antibacterial and antitumoral agents. Complex Schiff-Pr (29) with praseodymium showed antibacterial activity against *P. aeruginosa* and *S. aureus*. The complex showed IZD = 24 mm against both bacteria, which was comparable to that of streptomycin used as the standard drug (IZD = 25 mm) against *P. aeruginosa* and higher than that of the standard (IZD = 20 mm) against *S. aureus*. Complexes. Complex Schiff-Er (28) and Schiff-Yb (29) showed antibacterial activity, even though it was lower than Schiff-Pr (30).

Alqaasaimeh et al. (2023) [80] described three neutral lanthanides SB coordination complexes with lanthanides (Nd, Tb, and Dy) with (2-((p-tolylimino)methyl)phenol) SB. The antimicrobial activity was evaluated in vitro against Gram-positive bacteria *S. aureus*, Gram-negative (*E. coli*) using gentamicin and amikacin as standards against *S. aureus* and against the fungus *C. albicans* using nystatin as the standard. La, Lb, and Lc (31, 32, and 33) showed activity against bacteria and fungi. It is interesting to note that the free ligand was inactive against bacteria. Particularly, Lc (33) was the most active against *C. albicans*. 
Table 2. SBs complexes with inner transition metals (lanthanides and actinides) with antimicrobial activity.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="Schiff-Er" /></td>
<td>Schiff-Er (28)</td>
<td>IZD = 21 mm (<em>P. aeruginosa</em>)&lt;br&gt;IZD = 23 mm (<em>S. aureus</em>)</td>
<td>Andiappan et al. (2023) [79]</td>
</tr>
<tr>
<td><img src="image2" alt="Schiff-Pr" /></td>
<td>Schiff-Pr (29)</td>
<td>IZD = 24 mm (<em>P. aeruginosa</em>)&lt;br&gt;IZD = 24 mm (<em>S. aureus</em>)</td>
<td>Andiappan et al. (2023) [79]</td>
</tr>
</tbody>
</table>
Table 2. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="30" alt="Schiff-Yb" /></td>
<td>Schiff-Yb (30)</td>
<td>IZD = 22 mm (P. aeruginosa) IZD = 20 mm (S. aureus)</td>
<td>Andiappan et al. (2023) [79]</td>
</tr>
<tr>
<td><img src="31" alt="La" /></td>
<td>La (31)</td>
<td>MIC = 0.75 mg/mL (S. aureus ATCC 29213) MIC = 3 mg/mL (S. aureus ATCC 33591) MIC = 3 mg/mL (E. coli ATCC 25922)</td>
<td>Alqasaimeh et al. (2023) [80]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MIC = 1.5 mg/mL (P. aeruginosa ATCC 27853) MIC = 1.5 mg/mL (C. albicans ATCC 10231)</td>
<td></td>
</tr>
</tbody>
</table>
Table 2. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Structure" /></td>
<td>Lb (32)</td>
<td>MIC = 0.75 mg/mL (S. aureus ATCC 29213) &lt;br&gt; MIC = 3 mg/mL (S. aureus ATCC 33591) &lt;br&gt; MIC = 3 mg/mL (E. coli ATCC 25922) &lt;br&gt; MIC = 1.5 mg/mL (P. aeruginosa ATCC 27853) &lt;br&gt; MIC = 1.5 mg/mL (C. albicans ATCC 10231)</td>
<td>Alqasaimeh et al. (2023) [80]</td>
</tr>
<tr>
<td><img src="image2.png" alt="Structure" /></td>
<td>Lc (33)</td>
<td>MIC = 0.75 mg/mL (S. aureus ATCC 29213) &lt;br&gt; MIC = 3 mg/mL (S. aureus ATCC 33591) &lt;br&gt; MIC = 3 mg/mL (E. coli ATCC 25922) &lt;br&gt; MIC = 1.5 mg/mL (P. aeruginosa ATCC 27853) &lt;br&gt; MIC = 0.75 mg/mL (C. albicans ATCC 10231)</td>
<td>Alqasaimeh et al. (2023) [80]</td>
</tr>
</tbody>
</table>
Table 2. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Structure Image" /></td>
<td>[La$<em>2$(C$</em>{26}$H$_{28}$O$_2$N$_6$)$_2$(NO$_3$)$_6$]·6H$_2$O (34)</td>
<td>IZD = 32–35 mm (S. aureus) IZD = 24–28 mm (S. subtilis) IZD = 18–20 mm (E. coli) IZD = 18–20 mm (K. pneumoniae)</td>
<td>Hussein et al. (2023) [81]</td>
</tr>
<tr>
<td><img src="image2.png" alt="Structure Image" /></td>
<td>[Gd$<em>2$(C$</em>{26}$H$_{28}$O$_2$N$_6$)$_2$(NO$_3$)$_6$]·6H$_2$O (35)</td>
<td>IZD = 21–35 mm (S. aureus) IZD = 24–28 mm (S. subtilis) IZD = 21–24 mm (E. coli) IZD = 21–24 mm (K. pneumoniae)</td>
<td>Hussein et al. (2023) [81]</td>
</tr>
</tbody>
</table>
Table 2. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
</table>
| ![Structure 1](image1) | $[\text{Er}_2(\text{C}_{26}\text{H}_{28}\text{O}_2\text{N}_6)_2(\text{NO}_3)_6] \cdot 6\text{H}_2\text{O}$ (36) | IZD = 28–32 mm (\textit{S. aureus})  
IZD = 28–32 mm (\textit{S. subtilis})  
IZD = 18–20 mm (\textit{E. coli})  
IZD = 24–28 mm (\textit{K. pneumoniae}) | Hussein et al. (2023) [81] |
| ![Structure 2](image2) | \textit{UrO}_2\textit{SV} (37) | IZD = 18 mm (\textit{S. aureus})  
IZD = 15 mm (\textit{E. faecalis})  
IZD = 20 mm (\textit{K. pneumoniae})  
IZD = 15 mm (\textit{P. aeruginosa}) | Awolope et al. (2023) [82] |
Table 2. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
</table>
| ![Structure Image](Image) | ZrOSV (38) | IZD = 15 mm (*S. aureus*)  
IZD = 17 mm (*E. faecalis*)  
IZD = 17 mm (*K. pneumoniae*)  
IZD = 16 mm (*P. aeruginosa*) | Awolope et al. (2023) [82] |
Hussein et al. (2023) [81] described the synthesis and biological studies of complexes of lanthanides (lanthanum, neodymium, erbium, gadolinium, and dysprosium) with SBs deriving from antipyrine. Antibacterial studies were carried out at concentrations $10^{-3}$ M against *S. aureus*, *B. subtilis*, *E. coli*, and *K. pneumoniae*. The highest activity against *S. aureus* was found for $[\text{La}_2(C_{26}H_{26}O_8N_2)_{2}(\text{NO}_3)_6]6\text{H}_2\text{O}$ (34) and $[\text{Gd}_2(C_{26}H_{26}O_8N_2)_{2}(\text{NO}_3)_6]6\text{H}_2\text{O}$ (35), whereas $[\text{Er}_2(C_{26}H_{26}O_8N_2)_{2}(\text{NO}_3)_6]6\text{H}_2\text{O}$ (36) showed activity, lower than the other two, against both *S. aureus* and *B. subtilis*.

Avolope et al. (2023) [82] reported the synthesis and antibacterial and antioxidant activity of some SBs with transition metals and actinides. The antibacterial activity was evaluated against Gram-positive *S. aureus* and *E. faecalis* and Gram-negative *K. pneumoniae* and *P. aeruginosa*. The most interesting compounds of the study as antibacterials were UrO$_2$SV and ZrOSV (37 and 38). Specifically, UrO$_2$SV (37) showed higher activity against *S. aureus* and *K. pneumoniae* (nystatin was used as standard, IZD = 27 and 23 mm, respectively), whereas compound ZrOSV (38) showed slight activity against *E. faecalis* and *P. aeruginosa* (nystatin, IZD = 25 and 22 mm, respectively).

3. Chitosan SBs Complexes as Antimicrobials

Chitosan SBs have shown interesting biological activities [83] as being anticancer [84,85], antioxidant [86–88], antibacterial [89–92], and antidiabetic [93]. Some chitosan-based SBs are used for the removal of toxic metal ions from the aqueous medium, including Fe(III) [94], Pb(II) [95], Cu(II), Cd(II) [96], Cr(III) [97], and Cr(VI) [98,99]. Some authors also describe chitosan SB complexes with metals and their biological activities as antitumoral and antimicrobial. Specifically, an interesting study describes the synthesis of biopolymeric chitosan-supported SB complexes with Cu(II), Ni(II), and Zn(II) and their biological evaluation as antitumoral agents against MG-63 osteosarcoma cancer cell lines. The complexes were more active than pure chitosan against the cancer MG63 cell line [100]. Recently, some chitosan SBs-based polyelectrolyte complexes with graphene quantum dots have been described, along with their prospective biomedical applications as antibacterials. One compound, namely PE-G-3 (structure not shown), showed interesting activity against *Helicobacter pylori* measured by the in vitro inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitory assay, as long as its activity to enhance wound healing [101]. A recent study by Ignatova et al. (2022) [102] described the synthesis of an SB derivative (Ch-8Q) of chitosan and 8-hydroxyquinoline-2-carboxaldehyde and novel fibrous materials successfully obtained from Ch-8Q and polylactide (PLA) by one-pot electrospinning of their blend solution and the complexes of the mats with Cu(II) and Fe(III). The incorporation of Ch-8Q in the fibrous mats and complexation with Cu(II) and Fe(III) led to the ability to kill all *S. aureus* bacteria within 3 h of contact. Moreover, in contrast to the chitosan-containing mats, which only reduce the adhesion of pathogenic bacteria *S. aureus*, Ch-8Q-containing materials and their complexes inhibit bacterial adhesion.

Tao et al. (2023) [103] have recently reported an interesting study on SB deriving CS-CT-CCA complex (39) with natural citral (CT), chitosan (CS), and calcium citrate (CCA) and its activity against *Vibrio parahaemolyticus*, which is defined the “number one killer” of seafood products (Table 3). The complex, which had good dispersion properties and an excellent sustained released ability, was active against *V. parahaemolyticus* and increased the membrane permeability of *V. parahaemolyticus*, also determining the inhibition of biofilm-forming ability in a dose-dependent manner. CT mainly comes from the essential oil of lemon grass and has vigorous antibacterial activity: it was used for comparison against *V. parahaemolyticus* (MIC = $1024 \mu g/mL$) along with CS-CT (MIC = $256 \mu g/mL$) and ciprofloxacin (MIC = $4 \mu g/mL$).
Table 3. Chitosan SBs complexes with metals with antimicrobial activity.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>MIC or IZD</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CS-CT-CCa (39)</td>
<td>MIC = 128 µg/mL (V. parahaemolyticus ATCC 17802)</td>
<td>Tao et al. (2023) [103]</td>
<td></td>
</tr>
<tr>
<td>Ru(CVSBB)(H₂O₂)Cl₂ (40)</td>
<td>IZD = 11 mm (A. flavus) IZD = 12 mm (A. niger) IZD = 11 mm (P. chryogenum) IZD = 10 mm (F. oxysporum) IZD = 12 mm (T. viride)</td>
<td>Amirthaganesan et al. (2022) [104]</td>
<td></td>
</tr>
<tr>
<td>Ru(CSSBB)(H₂O₂)Cl₂ (41)</td>
<td>IZD = 14 mm (A. flavus) IZD = 12 mm (A. niger) IZD = 10 mm (P. chryogenum) IZD = 11 mm (F. oxysporum) IZD = 10 mm (T. viride)</td>
<td>Amirthaganesan et al. (2022) [104]</td>
<td></td>
</tr>
<tr>
<td>Ru(COSBB)(H₂O₂)Cl₂ (42)</td>
<td>IZD = 12 mm (A. flavus) IZD = 12 mm (A. niger) IZD = 11 mm (P. chryogenum) IZD = 10 mm (F. oxysporum) IZD = 12 mm (T. viride)</td>
<td>Amirthaganesan et al. (2022) [104]</td>
<td></td>
</tr>
</tbody>
</table>

Amirthaganesan et al. (2022) [104] reported a study on ruthenium(III) complexes derived from chitosan SBs (Ru(CVSBB)(H₂O₂)Cl₂ (40), Ru(CSSBB)(H₂O₂)Cl₂ (41) and Ru(COSBB) (H₂O₂)Cl₂ (42), and their antifungal activity evaluation against Aspergillus flavus, A. niger, Penicillium chryogenum, Fusarium oxysporum, and Trichoderma viride, by disc diffusion method.
Amphotericin-B was used as the standard drug (IZD = 22, 26, 20, 22, and 26 mm, respectively). Ruthenium(III) complexes showed higher antifungal activity than their parent ligands.

4. Metal Complexes with SBs with Catalytic Activity

Metal complexes with SBs are often studied and used for their catalytic activities. Table 4 summarizes the compounds endowed with this activity most recently reported. Bikas et al. (2023) [105] described the synthesized and characterization of two dinuclear Zn(II) complexes with SBs, namely Zn$_2$(L$^1$)$_2$(N$_3$)$_2$ (43) and Zn$_2$(L$^2$)$_2$(N$_3$)$_2$ (44), derived from 4-aminoantipyrine. The complexes were demonstrated to be active catalysts in the reaction of benzonitrile and sodium azide for the synthesis of tetrazoles. The model compound for tetrazoles used was 5-phenyl-1H-tetrazole. Neshat et al. (2023) [106] reported the synthesis and characterization of a Cu(II) complex CuL$_2$ (45) with a bidentate SB derived from Ortho-vanillin. The catalytic activity was studied in the oxidation of selected primary and secondary alcohols. The complex showed higher performance in the oxidations of secondary alcohols under mild reaction conditions. The catalytic activity in the oxidation of secondary aromatic alcohols was shown to be higher with substrates containing electron-withdrawing substituents, whereas it was low in the oxidation of aliphatic primary alcohols. The authors suggested a radical mechanism for the catalytic activity. Rabiei et al. [107] recently described a functionalized metal–organic-framework nanocatalyst, which is an SB complex with Cu and Pd [Cu(BDC-NH$_2$)$_2$@Schiff base Pd(II) (46)], for C–N coupling. It was obtained via a two-step post-synthetic modification reaction of Cu(BDC-NH$_2$) with N,N'-bis(5-formylpyrrol-2-ylmethyl) homopiperazine followed by Pd ion immobilization. Optimization of the C–N coupling reaction of p-tolyliboronic acid with 1-(2-oxo-2-phenylethyl)-1H-pyrrole-2-carbonitrile in the presence of this catalyst was studied. The catalyst showed several advantages, being robust and stable under the reaction conditions, easily separated from the mixture, capable of being reused up to seven times, and producing products with high yields. Jabbari et al. [108] described the preparation of a V(O)-SB complex on MCM-41 (Mobil Composition of Matter No. 41) as a stable, efficient, reusable, and chemoselective nanocatalyst for the oxidative coupling of thiols and oxidation of sulfides. The complex, named V(O)-5NSA-MCM-41 (47), can be used for the synthesis of disulfide and sulfoxide derivatives using hydrogen peroxide (H$_2$O$_2$) as a biocompatibility, inexpensive, and available oxidant. Products were obtained with good yields. Recently, the development of magnetic Fe$_3$O$_4$-chitosan immobilized Cu(II) SB catalyst [Fe$_3$O$_4$@CS@Schiffbase@Cu (48)] has been reported [109]. This heterogeneous catalyst has been demonstrated to be an efficient and reusable catalyst for microwave-assisted one-pot synthesis of propargylamines via the A$^3$ coupling reaction of aldehydes, alkynes, and amines. The catalyst was efficiently recyclable and reusable even after six cycles and proved its superiority over homogenous catalysts by producing 95% of the desired product.
Table 4. SBs complexes with transition metals with catalytic activity.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>Catalyzed Reactions</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Structure 1" /></td>
<td>[Zn$_2$(L$^1$)$_2$(N$_3$)$_2$] (43)</td>
<td>Synthesis of tetrazoles</td>
<td>Bikas et al. (2023) [105]</td>
</tr>
<tr>
<td><img src="image2.png" alt="Structure 2" /></td>
<td>[Zn$_2$(L$^2$)$_2$(N$_3$)$_2$] (44)</td>
<td>Synthesis of tetrazoles</td>
<td>Bikas et al. (2023) [105]</td>
</tr>
</tbody>
</table>
Table 4. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>Catalyzed Reactions</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.png" alt="Structure" /></td>
<td>CuL₂ (45)</td>
<td>Oxidation of secondary alcohols</td>
<td>Neshat et al. (2023) [106]</td>
</tr>
<tr>
<td><img src="image2.png" alt="Structure" /></td>
<td>Cu(BDC-NH₂)@Schiff base Pd(II) (46)</td>
<td>C–N coupling reactions</td>
<td>Rabiei et al. (2023) [107]</td>
</tr>
<tr>
<td><img src="image3.png" alt="Structure" /></td>
<td>V(O)-5NSA-MCM-41 (47)</td>
<td>Oxidative coupling of thiols and oxidation of sulfides</td>
<td>Jabbari et al. (2023) [108]</td>
</tr>
</tbody>
</table>
Table 4. Cont.

<table>
<thead>
<tr>
<th>Structure</th>
<th>Compd</th>
<th>Catalyzed Reactions</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="Structure Image" /></td>
<td>Fe₃O₄@CS@Schiffbase@Cu (48)</td>
<td>A₃ coupling reaction under microwave irradiation</td>
<td>Hasan et al. (2023) [109]</td>
</tr>
</tbody>
</table>
5. Summary

SBs are a well-documented class of ligands able to bind almost all metals of the periodic table. They represent an ideal ligand scaffold since they have shown a large spectrum of biological activities, including antitumor, antiviral, antimicrobial, and anti-inflammatory activities. Complexes of SBs with transition metals have shown numerous applications as catalysts in various biological systems, corrosion inhibitors, polymers, and dyes. Schiff base complexes of transition metal ions catalyze several homogeneous and heterogeneous reactions in which numerous substrates, such as sulfides, aldehydes, phenols, thioanisoles, styrenes, and so on, are converted into the important precursors of drugs and materials. These reactions are usually conducted under mild and stable conditions, giving the desired products in high yields. Furthermore, another advantage that must be considered is that they can be simply separated from the reaction mixture and reused several times.

Interestingly, SBs metal complexes are used in therapeutic or biological applications either as potential drug candidates or diagnostic probes and analytical tools. Their numerous activities, including antitumoral, antimicrobial, antioxidant, and neuroprotective ones, are widely documented. Since AMR is a mounting threat to health and well-being globally, the main aim of this review was to focus, explore, and summarize the most recent available research studies regarding the antimicrobial activity exerted by these compounds. Some of the described compounds showed in vitro antimicrobial activities comparable to, and sometimes higher than, the reference drugs. The antimicrobial activity of metal complexes with SBs and their known anticorrosive potential may have great potential for their future application in several types of surgeries. Finally, the identification of new compounds belonging to this class may represent a new strategy to limit or overcome the occurrence of resistant strains, counteracting antibiotic resistance. The reviewed data clearly suggest that SBs metal complexes deserve particular consideration for their application in different fields, including medicinal chemistry and catalysis.

Author Contributions: Conceptualization, A.C. and M.S.S.; writing—original draft preparation, D.I. and J.C.; methodology, D.I.; A.M. and F.G.; validation, J.C. and C.S.; writing—review and editing, A.C. and C.S.; supervision, P.L. and M.S.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

4. Afshari, F.; Ghomi, E.R.; Dinari, M.; Ramakrishna, S. Recent advances on the corrosion inhibition behavior of Schiff base compounds on mild steel in acidic media. ChemistrySelect 2023, 8, e202203231. [CrossRef]
6. Alam, M.Z.; Khan, S.A. A review on Schiff base as a versatile fluorescent chemo-sensors tool for detection of Cu^{2+} and Fe^{3+} metal ion. J. Fluoresc. 2023; in press. [CrossRef]
7. Aytac, S.; Gundogdu, O.; Bingol, Z.; Gulcin, I. Synthesis of Schiff bases containing phenol ring and investigation of their antioxidant capacity, anticholinesterase, butyrylcholinesterase and carbonic anhydrase inhibition properties. Pharmaceutics 2023, 15, 779. [CrossRef]


33. Mokhtari, P.; Mohammadnezhad, G. Anti-cancer properties and catalytic oxidation of sulfides based on vanadium(V) complexes 


Zhang, Z.; Song, Q.; Jin, Y.; Feng, Y.; Li, J.; Zhang, K. Advances in Schiff base and its coating on metal biomaterials—A review. *Metals* 2023, 13, 386. [CrossRef]


Rakhtshah, J. A comprehensive review on the synthesis, characterization, and catalytic application of transition-metal Schiff-base complexes immobilized on magnetic Fe3O4 nanoparticles. *Coordin. Chem. Rev.* 2022, 467, 214614. [CrossRef]


Soroceanu, A.; Bargan, A. Advanced and biomedical applications of Schiff-base ligands and their metal complexes: A review. *Crysalts* 2022, 12, 1436. [CrossRef]

Kar, K.; Ghosh, D.; Kabí, B.; Chandra, A. A concise review on cobalt Schiff base complexes as anticancer agents. *Polyhedron* 2022, 222, 115890. [CrossRef]


Mokhtari, P.; Mohammadnezhad, G. Anti-cancer properties and catalytic oxidation of sulfides based on vanadium(V) complexes of unprotected sugar-based Schiff-base ligands. *Polyhedron* 2022, 215, 115655. [CrossRef]


44. Aragón-Muriel, A.; Reyes-Márquez, V.; Cañavera-Buelvas, F.; Parra-Unda, J.R.; Cueni-Cabezas, F.; Polo-Cerón, D.; Colorado-Peralta, R.; Suárez-Moreno, G.V.; Aguilar-Castillo, B.A.; Morales-Morales, D. Pincer complexes derived from tridentate Schiff bases for their use as antimicrobial antimetabolicals. Inorganics 2022, 10, 134. [CrossRef]


54. Akitsu, T. Hybrid or component?—Schiff base complexes and laccase. Compounds 2022, 2, 307–310. [CrossRef]


90. Hassan, M.A.; Tamer, T.M.; Omer, A.M.; Baset, W.M.; Abbas, E.; Mohy-Eldin, M.S. Therapeutic potential of two formulated novel chiton derivatives with prominent antimicrobial activities against virulent microorganisms and safe profiles toward fibroblast cells. *Int. J. Pharm.* 2023, 634, 122649. [CrossRef]


95. Wei, W.; Wu, H.; Chen, Y.; Zhong, K.; Feng, L. Application of new chitosan 2,4-dihydroxyacetophenone Schiff base @SrFe$_2$O$_3$ nanocomposites for removal of Pb(II) ion from aqueous solution. *Int. J. Biol. Macromol.* 2023, 226, 336–344. [CrossRef]


97. Mahmoud, R.K.; Mohamed, F.; Gaber, E.; Abdel-Gawad, O.F. Insights into the synergistic removal of copper(II), cadmium(II), and chromium(III) ions using modified chitosan based on Schiff bases-g-poly(acrylonitrile). *ACS Omega* 2022, 7, 42012–42026. [CrossRef] [PubMed]


**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.